About Daré Bioscience
Daré Bioscience is a company based in San Diego (United States) founded in 2005. The company has 23 employees as of December 31, 2024. Daré Bioscience has completed 2 acquisitions, including Cerulean Pharma and Microchips Biotech. Daré Bioscience offers products and services including XACIATO and Drug Delivery Platform. Daré Bioscience operates in a competitive market with competitors including Atossa Therapeutics, Olema Oncology, PIQUR, Aspivix and Minerva Biotechnologies, among others.
- Headquarter San Diego, United States
- Employees 23 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Dare Bioscience, Inc.
-
Annual Revenue
$9.78 K (USD)-99.65as on Dec 31, 2024
-
Net Profit
-$4.05 M (USD)86.56as on Dec 31, 2024
-
EBITDA
-$22.84 M (USD)25.85as on Dec 31, 2024
-
Latest Funding Round
$3.6 M (USD), Grant
Nov 24, 2025
-
Investors
NIH
& 3 more
-
Employee Count
23
as on Dec 31, 2024
-
Investments & Acquisitions
Cerulean Pharma
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Daré Bioscience
Daré Bioscience is a publicly listed company on the NASDAQ with ticker symbol DARE in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Daré Bioscience
Daré Bioscience offers a comprehensive portfolio of products and services, including XACIATO and Drug Delivery Platform.
Treatment for vaginal infections using clindamycin phosphate.
Wireless system for user-controlled drug administration.
People of Daré Bioscience
Unlock access to complete
Unlock access to complete
Funding Insights of Daré Bioscience
Investors in Daré Bioscience
Daré Bioscience has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include NIH, Gates Foundation and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Charitable foundation investments on poverty reduction and healthcare
|
Locked | Locked | Locked | |
|
Drug discovery services are provided to the biopharma sector.
|
Locked | Locked | Locked |
Investor details for Daré Bioscience
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Daré Bioscience
Daré Bioscience has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Cerulean Pharma and Microchips Biotech.
Investment portfolio details for Daré Bioscience
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Nanoparticle-drug conjugates are developed to target tumors and reduce toxicity.
|
Locked | Locked | 2006 | Locked | |
|
Microchip implants for wireless drug delivery are developed.
|
Locked | Locked | 1999 | Locked |
Complete acquisition details for Daré Bioscience
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Daré Bioscience
Detailed financials for Daré Bioscience
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Daré Bioscience Comparisons
Peer comparison for Daré Bioscience
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Daré Bioscience
Daré Bioscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Atossa Therapeutics, Olema Oncology, PIQUR, Aspivix and Minerva Biotechnologies, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drugs for breast cancer treatment and prevention are developed.
|
|
| Locked | Locked | Locked |
Drug therapeutics for breast cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Anti-cancer drugs are developed via PI3K and mTOR inhibition targeting.
|
|
| Locked | Locked | Locked |
A next-generation suction-based cervical device for gynecology is provided.
|
|
| Locked | Locked | Locked |
Cell therapy and antibodies are developed to treat cancer.
|
Detailed competitors of Daré Bioscience
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Daré Bioscience
Complete news archive for Daré Bioscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Daré Bioscience
Daré Bioscience was founded in 2005 and raised its 1st funding round 12 years after it was founded.
Daré Bioscience is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
As of Dec 31, 2024, the latest employee count at Daré Bioscience is 23.
Annual revenue of Daré Bioscience is $9.78K as on Dec 31, 2024.
Dare Bioscience was founded in 2005 in San Diego, United States, and operates in the biotechnology sector focused on womens reproductive health. Non-hormonal contraceptive options are developed, with the lead product Ovaprene designed as an intravaginal ring. This ring incorporates a permeable mesh barrier to sperm and releases spermiostatic agents, including ascorbic acid and ferrous gluconate, for localized pH buffering and sperm immobilization over several weeks.
Daré Bioscience's top competitors include Atossa Therapeutics, Minerva Biotechnologies and Olema Oncology.
Daré Bioscience offers XACIATO and Drug Delivery Platform.
Yes, Daré Bioscience is publicly traded on NASDAQ under the ticker symbol DARE.
Daré Bioscience has made 2 acquisitions, including Cerulean Pharma, and Microchips Biotech.
Daré Bioscience has 4 investors. Key investors include NIH, Gates Foundation, HHS, and NICHD.
The ticker symbol of Daré Bioscience is DARE on NASDAQ.